首頁 > 市場調查報告書 > 製藥

藥物開發疫苗開發業務受託機關

疫苗契約製造市場規模、佔有率和成長分析（按研發階段、應用、工作流程、疫苗類型、產品類型、最終用戶、服務類型和地區分類）—2025-2032年產業預測

市場調查報告書

商品編碼

1865330

疫苗契約製造市場規模、佔有率和成長分析（按研發階段、應用、工作流程、疫苗類型、產品類型、最終用戶、服務類型和地區分類）—2025-2032年產業預測

Vaccine Contract Manufacturing Market Size, Share, and Growth Analysis, By Phase, By Application, By Workflow, By Vaccine Type, By Type, By Product Type, By End User, By Service Type, By Region - Industry Forecast 2025-2032

出版日期: 2025年11月06日 | 出版商:

SkyQuest | 英文 190 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2023 年，全球疫苗契約製造市場規模將達到 28 億美元，到 2024 年將成長至 30.4 億美元，到 2032 年將成長至 58.3 億美元，在預測期（2025-2032 年）內複合年成長率為 8.5%。

全球疫苗接種計畫的擴展、創新疫苗技術的進步、對疫情防範的高度重視以及研發投入的不斷增加，都在推動全球疫苗契約製造市場的發展。隨著中低收入國家啟動新的疫苗接種計劃，對契約製造的需求尤其強烈。 mRNA、病毒載體和重組蛋白等創新疫苗平台預計將成為市場成長的主要驅動力。各國政府和衛生組織的政策措施和資金投入旨在加強生產基礎設施，以提升危機應變能力。然而，基礎設施成本上升、監管嚴格、熟練勞動力短缺以及供應鏈脆弱性等挑戰仍然存在，這些都可能阻礙市場擴張。

全球疫苗契約製造市場促進因素

全球疫苗契約製造市場的主要促進因素是公共衛生危機（例如流行病和新興感染疾病）引發的對快速疫苗研發和生產能力的日益成長的需求。隨著各國政府和組織將疫苗的可及性和速度放在首位，對高效契約製造服務的需求也隨之激增。生物技術公司與合約契約製造之間的合作能夠實現擴充性和靈活性，使其能夠快速適應不斷變化的健康威脅。生物製造技術的進步進一步強化了這一趨勢，提高了生產能力並簡化了流程，從而推動了契約製造行業的顯著成長。

限制全球疫苗契約製造市場的因素

全球疫苗契約製造市場的主要限制因素之一是疫苗生產受到嚴格的法律法規結構。製造商必須遵守衛生當局製定的嚴格品管標準和監管規定，這會增加營運成本，延長產品研發和核准時間。合規所需的大量資金構成了一道壁壘，阻礙了中小企業進入市場，並可能限制整體市場成長潛力。此外，不同地區的監管要求也使生產流程更加複雜，為契約製造製造商高效滿足多樣化的市場需求帶來了更多挑戰。

全球疫苗契約製造市場趨勢

全球疫苗契約製造市場正經歷著向模組化和靈活化生產設施的重大轉變，這反映了業界對敏捷性和擴充性的需求。供應商正在加速採用模組化潔淨室、預製單元和一次性生物反應器，從而能夠快速應對市場波動並支援多產品生產。這一趨勢不僅提高了營運效率，還使企業能夠根據新的需求或疫苗配方的出現快速調整產能。因此，對適應性生產解決方案的關注預計將在塑造疫苗生產的未來和供應鏈韌性方面發揮關鍵作用。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2024 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2024 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2022-2024年營收年比比較

主要企業簡介

Lonza Group（Switzerland）
Catalent, Inc.（USA）
Thermo Fisher Scientific Inc.（USA）
Samsung Biologics Co., Ltd.（South Korea）
WuXi Biologics（China）
FUJIFILM Diosynth Biotechnologies（Japan）
Emergent BioSolutions（USA）
IDT Biologika GmbH（Germany）
Charles River Laboratories（USA）
AGC Biologics（USA）
Boehringer Ingelheim BioXcellence（Germany）
Recipharm AB（Sweden）
CordenPharma（Germany）
KBI Biopharma（USA）
Merck KGaA（Germany）
Curia Global, Inc.（USA）
Siegfried Holding AG（Switzerland）
Novasep（France）
Richter-Helm BioLogics GmbH & Co. KG（Germany）
Syngene International Limited（India）

結論與建議

簡介目錄

Product Code: SQMIG35J2177

Global Vaccine Contract Manufacturing Market size was valued at USD 2.8 billion in 2023 and is poised to grow from USD 3.04 billion in 2024 to USD 5.83 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032).

The global vaccine contract manufacturing market is being significantly propelled by the worldwide expansion of vaccination initiatives, advancements in innovative vaccine technologies, and a strong focus on pandemic preparedness, coupled with increasing investments in research and development. The rising demand for contract manufacturing is particularly prominent in low- and middle-income countries launching new immunization programs. Innovative vaccine platforms, such as mRNA, viral vectors, and recombinant proteins, are set to enhance market growth. Policy commitments and funding from governments and health organizations aim to strengthen manufacturing capabilities for crisis resilience. However, challenges remain, including high infrastructure costs, stringent regulations, shortages of skilled labor, and vulnerabilities within the supply chain that could hinder market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccine Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccine Contract Manufacturing Market Segments Analysis

Global Vaccine Contract Manufacturing Market is segmented by Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type and region. Based on Phase, the market is segmented into Preclinical, Clinical and Commercial. Based on Application, the market is segmented into Human Use and Veterinary. Based on Workflow, the market is segmented into Downstream, Upstream and Others. Based on Vaccine Type, the market is segmented into Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based. Based on Type, the market is segmented into Viral, Bacterial and Others. Based on Product Type, the market is segmented into Single Vaccines and Combination Vaccines. Based on End User, the market is segmented into Biopharmaceutical Companies and Research Academies & Government Institutes. Based on Service Type, the market is segmented into Fill-Finish and Bulk Products. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vaccine Contract Manufacturing Market

A key market driver for the Global Vaccine Contract Manufacturing Market is the increasing demand for rapid vaccine development and production capabilities, spurred by public health crises such as pandemics and emerging infectious diseases. As governments and organizations prioritize vaccine accessibility and speed, the need for efficient contract manufacturing services has surged. The collaboration between biotechnology companies and contract manufacturers enables scalability and flexibility, allowing for the swift adaptation to changing health threats. This trend is further amplified by advancements in biomanufacturing technologies, enhancing production capacities and streamlining processes, thus driving significant growth in the contract manufacturing sector.

Restraints in the Global Vaccine Contract Manufacturing Market

One of the key market restraints for the global vaccine contract manufacturing market is the stringent regulatory framework governing vaccine production. Manufacturers must adhere to rigorous quality control standards and regulatory compliance imposed by health authorities, which can lead to increased operational costs and elongated timelines for product development and approval. This can deter smaller companies from entering the market due to the high capital required for compliance, limiting the overall growth potential. Additionally, variable regulatory requirements across different regions may complicate manufacturing processes, creating further challenges for contract manufacturers in meeting diverse market demands efficiently.

Market Trends of the Global Vaccine Contract Manufacturing Market

The Global Vaccine Contract Manufacturing market is witnessing a significant shift towards modular and flexible manufacturing facilities, reflecting the industry's need for agility and scalability. Providers are increasingly adopting modular cleanrooms, prefabricated units, and single-use bioreactors, enabling them to respond swiftly to market fluctuations and support multi-product manufacturing. This trend not only enhances operational efficiency but also allows companies to swiftly pivot their production capabilities in response to emerging demands or new vaccine formulations. As a result, the focus on adaptable manufacturing solutions is set to play a crucial role in shaping the future of vaccine production and supply chain resilience.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Vaccine Contract Manufacturing Market Size by Phase & CAGR (2025-2032)

Market Overview
Preclinical
Clinical
Commercial

Global Vaccine Contract Manufacturing Market Size by Application & CAGR (2025-2032)

Market Overview
Human Use
Veterinary

Global Vaccine Contract Manufacturing Market Size by Workflow & CAGR (2025-2032)

Market Overview
Downstream
Upstream
Others

Global Vaccine Contract Manufacturing Market Size by Vaccine Type & CAGR (2025-2032)

Market Overview
Attenuated
Inactivated
Subunit-based
Toxoid-based
DNA-based

Global Vaccine Contract Manufacturing Market Size by Type & CAGR (2025-2032)

Market Overview
Viral
Bacterial
Others

Global Vaccine Contract Manufacturing Market Size by Product Type & CAGR (2025-2032)

Market Overview
Single Vaccines
Combination Vaccines

Global Vaccine Contract Manufacturing Market Size by End User & CAGR (2025-2032)

Market Overview
Biopharmaceutical Companies
Research Academies & Government Institutes

Global Vaccine Contract Manufacturing Market Size by Service Type & CAGR (2025-2032)

Market Overview
Fill-Finish
Bulk Products

Global Vaccine Contract Manufacturing Market Size & CAGR (2025-2032)

North America (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- US
- Canada
Europe (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- Brazil
- Rest of Latin America
Middle East & Africa (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Lonza Group (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FUJIFILM Diosynth Biotechnologies (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IDT Biologika GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AGC Biologics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim BioXcellence (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recipharm AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CordenPharma (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KBI Biopharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curia Global, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siegfried Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novasep (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Richter-Helm BioLogics GmbH & Co. KG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Syngene International Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments